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Kinase-independent function of RIP1, critical formature
T-cell survival and proliferation
John P Dowling1, Yubo Cai1,3, John Bertin2, Peter J Gough2 and Jianke Zhang*,1
The death receptor, Fas, triggers apoptotic death and is essential for maintaining homeostasis in the peripheral lymphoid organs.
RIP1 was originally cloned when searching for Fas-binding proteins and was later shown to associate also with the signaling
complex of TNFR1. Although Fas exclusively induces apoptosis, TNFR1 primarily activates the pro-survival/pro-inflammatory NF-
κB pathway. Mutations in Fas lead to lymphoproliferative (lpr) diseases, and deletion of TNFR1 results in defective innate immune
responses. However, the function of RIP1 in the adult lymphoid system has not been well understood, primarily owing to perinatal
lethality in mice lacking the entire RIP1 protein in germ cells. This current study investigated the requirement for RIP1 in the T
lineage using viable RIP1 mutant mice containing a conditional and kinase-dead RIP1 allele. Disabling the kinase activity of RIP1
had no obvious impact on the T-cell compartment. However, T-cell-specific deletion of RIP1 led to a severe T-lymphopenic
condition, owing to a dramatically reduced mature T-cell pool in the periphery. Interestingly, the immature T-cell compartment in the
thymus appeared intact. Further analysis showed that mature RIP1− /− T cells were severely defective in antigen receptor-induced
proliferative responses. Moreover, the RIP1− /− T cells displayed greatly increased death and contained elevated caspase
activities, an indication of apoptosis. In total, these results revealed a novel, kinase-independent function of RIP1, which is
essential for not only promoting TCR-induced proliferative responses but also in blocking apoptosis in mature T cells.
Cell Death and Disease (2016) 7, e2379; doi:10.1038/cddis.2016.307; published online 29 September 2016
The pro-survival signaling pathways provide protection
against cell death responses at various stages during
T lymphopoiesis as well as maintenance of the mature
population.1,2 Apoptosis is a major programmed cell death
pathway, which can be induced through either intrinsic or
extrinsic signals.3 Under normal circumstances, the pro-
survival and apoptosis signaling pathways are tightly regu-
lated, which ensures generation of diverse T-cell repertoires,
while avoiding autoimmunity. For instance, the Bcl-2 and
Bcl-XL genes, which inhibit the intrinsic apoptotic pathway,
are essential for both T-cell development and peripheral
maintenance.4,5 However, lack of cell death, as in the case
of inactivation of Bim, a pro-apoptotic protein of the Bcl-2
family, results in lymphoproliferative and autoimmune
diseases.6 The extrinsic pathway of apoptosis is triggered
through cell receptors, including Fas/Apo-1 and tumor
necrosis factor receptor 1 (TNFR1). Whereas Fas is a
professional death receptor, TNFR1 primarily signals the
pro-survival pathway by activating NF-κB, which also pro-
motes inflammation.7,8
Receptor-interacting protein (RIP or RIP1) was originally
cloned as a potential Fas-interacting protein.9 However, later
studies found that lack of RIP1 has no effect on Fas-induced
apoptosis.10,11 Subsequently, RIP1 was also found to associ-
ate with the signaling complex of TNFR1.12 It was shown that
RIP1 deficiency disrupts NF-κB activation induced by TNFR1
in primary mouse embryonic fibroblast cells or human Jurkat T
lymphoma cells.10,11 Several functional domains of RIP1 have
been defined. In particular, RIP1 contains a serine/threonine
kinase domain (KD) at the amino-terminus and a death
domain (DD) at the carboxy-terminus. The intermediate
domain, but not the protein serine/threonine KD of RIP1, is
required for the activation of NF-κB.13 The DD of RIP1
interacts with the DD of TNFR1-associated death domain
(TRADD) protein, a signaling adaptor, leading to both
apoptosis and NF-κB activation.12 Therefore, RIP1 may serve
as a scaffold protein in addition to being a protein serine/
threonine kinase.
The function of the KD of RIP1 remained unknown until the
landmark work by Holler et al.,14 implicating a novel function for
RIP1 in a caspase-independent cell death process with certain
characteristics of necrosis, namely necroptosis. Importantly,
mutations targeting the kinase activity of RIP1 abolish
necroptotic cell death induced by TNFR1. The in vivo role of
RIP1-mediated necroptosiswas first revealed by analysis of the
embryonic defect displayed by mice lacking the Fas-associated
death domain (FADD) protein.15 The FADD adaptor protein
relays exclusively apoptotic signals in the pathways triggered
by Fas, TNFR1, and TNF-related apoptosis-inducing ligand
receptors (TRAIL-Rs or DR4/5).16–18Whereas none of the DRs
are essential for mouse development, FADDdeficiency resulted
in midgestation death of mouse embryos.19,20 Interestingly,
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when RIP1 is absent, normal embryonic development is
restored in FADD− /− mice,15 indicating that FADD− /− embryo-
nic lethality is caused by RIP1-dependent necroptosis.
Although normal during embryogenesis, RIP1− /− FADD− /−
double knockout (DKO) mice display perinatal lethality,15
similar to the phenotype of RIP1− /− single knockout mice.10
In contrast, deletion of a RIP1-related protein kinase, RIP3,
fully restores normal embryonic as well as postnatal develop-
ment in FADD− /− mice.21 Recent studies demonstrated that
RIP1− /−mice can only reach adulthood when both FADD and
RIP3 are absent, indicating that RIP1 protects neonatal cells
from FADD-mediated apoptosis and RIP3-dependent
necroptosis.22–25 Importantly, FADD− /− RIP3− /− DKO mice
and RIP1− /− FADD− /− RIP3− /− triple knockout mice develop
age-dependent lymphadenopathy and splenomegaly, remi-
niscent of the lymphoproliferative (lpr) disease displayed by
Fas− /− mice. Therefore, both apoptosis and necroptosis are
essential for homeostasis in the peripheral lymphoid organs.
Previous studies have indicated that RIP1 is essential for
T-cell development, because RIP1-deficient fetal liver cells fail
to reconstitute the T-cell compartment in immunodeficient
recipient mice.15,26 A recent study showed that lack of RIP1 in
hematopoietic stem cells and progenitors (HSCs/Ps) leads to
a severe defect in hematopoiesis.27 However, the temporal
requirement for RIP1, particularly at postlineage commitment
stages, remains unclear. In the current study, T lineage-
specific deletion of RIP1 revealed a novel stage-specific
requirement for RIP1 to protect T cells from apoptosis as well
as to allow normal proliferative responses.
Results
RIP1 is dispensable in thymic immature T cells but
essential for mature T-cell maintenance. In previous
studies, deletion of RIP1 in germ cells resulted in perinatal
lethality,10 and few mature T cells were generated from
RIP1− /− fetal liver cells.15,26 More recently, studies found
deletion of RIP1 in HSCs/Ps led to lymphocyte deficiency.27
However, it remains unclear what role RIP1 has in T cells
during postlineage commitment stages. To this end, a mouse
line (RIP1f/f) carrying a conditional knockout allele of RIP1
was used in the current study, in which exon 3 encoding part
of the KD of RIP1 was flanked by two loxP sites.28 Moreover,
the lysine 45 residue was changed to alanine (K45A) in the
floxed exon 3 to disable the kinase activity of RIP1 and
thereby interrupt its necroptotic function. The lymphoid
compartment of K45A mice was analyzed. Total cellularity
of the thymus, spleen, and lymph nodes were comparable
between K45A mutant and control RIP1+/+ mice (Figure 1a).
Flow cytometric analysis showed that the T-cell subsets in the
thymus, spleen, and lymph nodes of K45A mutant mice were
similar to those in RIP1+/+ control mice (Figure 1b). Therefore,
the RIP1 conditional allele containing the K45A mutation
does not have a detectable effect on T-cell development and
maturation.
Western blotting analysis was then performed, and it
showed that the RIP1f/f mice express the K45A mutant RIP1
protein at levels similar to those of the endogenous RIP1
protein in control RIP1+/+ mice (Figures 2a and b). Therefore,
the loxP sites and the K45A mutation do not affect the gene
expression or protein stability of RIP1. To induce T cell-specific
deletion of RIP1, we crossed the LckCre transgene29 into the
RIP1f/f mice (Figure 2a). LckCre-mediated deletion of floxed
alleles is initiated at the pro/pre-T-cell stage, as shown in our
previous study.30 Western blotting analysis showed that the
expression of RIP1 was reduced to minimal levels in the
thymus of RIP1f/f LckCre+ mutant mice compared with control
mice (fourth lane, Figure 2b). This indicates that the LckCre
activity leads to efficient deletion of RIP1 in the T lineage in the
thymus. Hereafter, RIP1f/f LckCre+ is designated RIP1t− /−
mice and RIP1f/f mice are the same as RIP1K45A/K45A mice.
The RIP1t− /− mice live to adulthood with no obvious
difference from littermate controls by appearance or body
Figure 1 The kinase activity of RIP1 in T cells. (a) Cells were isolated from the
indicated lymphoid organs of wild-type RIP1+/+ mice and mutant mice homozygous for
the K45A mutation, and the cells were enumerated. Error bars are average±S.E.M.
(n= 5). P-values 40.05. (b) T-cell subsets of the indicated lymphoid organs were
analyzed by two-color flow cytometry upon staining for the CD4 and CD8 T lineage
markers. Representative of at least five independent experiments
T-cell death regulation by RIP1
JP Dowling et al
2
Cell Death and Disease
weight (data not shown). The total cellularity of the thymus,
spleen, and lymph nodes of RIP1t− /− mice were not
significantly different from that in control mice (Figure 2c),
and the organ size was normal by appearance and weight
(Supplementary Figure S1). Flow cytometric analysis was
then performed upon staining cells of the primary and
peripheral lymphoid organs for CD3 and B220. The percen-
tages of T-cell populations (CD3+) in the periphery (the spleen
and lymph nodes) were dramatically decreased in RIP1t− /−
mutant mice, in comparison with control littermates
(Figure 2d). As a result, the absolute T-cell numbers in the
mutant spleen (10.7 × 106±1.5) and lymph nodes
(5.6 × 106±0.9) were dramatically lower than RIP1+/+ T-cell
numbers in the spleen (36.6 × 106± 2.7) and lymph node
(17.9 × 106±0.8) and RIP1K45A/K45A T-cell numbers in the
spleen (36.2 × 106±2.5) and lymph node (20.9 × 106±1.8)
(Figure 3a). This T lymphopenic condition resulted in a
compensatory expansion and significant increase of B cells
in the RIP1t− /− lymph node (Figure 3b) while the myeloid
populations of these organs remained unchanged
(Supplementary Figure S2). In total, RIP1 deletion leads to
more than three-fold reduction of mature T cells in the
periphery.
Further flow cytometric analysis of the T lineages was
performed, and it showed that the percentages of pro/pre-
T cells (CD4−CD8−), immature T cells (CD4+CD8+), and
mature CD4+ andCD8+ T cellswere similar betweenRIP1t− /−
mutant mice and RIP1+/+ and RIP1K45A/K45A control mice
Figure 2 T-cell-specific deletion of RIP1. (a) Genotyping by PCR of mouse ear DNA showing genotypes generated from a RIP1+/f × RIP1+/f Lckcre+ mating cross. (b) Western
blotting analysis of RIP1 in thymocytes from mice of the indicated genotypes. Ponceus S staining was performed as protein loading/transfer control. (c) Total organ cellularity of
RIP1t− /− mutant mice (filled circles) and RIP1+/+ control mice (open circles) are shown. Error bars are average±S.E.M. P-values40.05. (d) Representative two-color flow
cytometric plots showing the T cell (CD3+) and B cell (B220+) populations in the indicated peripheral lymphoid organs
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Figure 3 Analysis of T-cell populations in RIP1t− /− mice. (a) Absolute T cell (CD3+) and (b) B cell (B220+) numbers in the spleen and lymph nodes of mutant and control
mice. *Po0.05, ***Po0.001, NS= not significant. (c) T-cell subsets of the indicated lymphoid organs were analyzed by flow cytometry upon staining for the CD4 and CD8 T
lineage markers or (d) CD62L. Data represents at least six independent experiments
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(Figure 3c). However, dramatic reductions in the percentages
of both CD4+ and CD8+ lineages of mature T cells were
observed in peripheral lymph tissues of RIP1t− /− mice,
including the spleen and lymph nodes (Figure 3c). Interest-
ingly, a higher percentage of T cells in RIP1t− /− mice
displayed lower expression of CD62L compared with control
mice (Figure 3d).
RIP1 is required for proliferative responses in mature
T cells. Stimulation through the T-cell antigen receptor (TCR)
leads to proliferative responses in mature T cells. To
determine whether RIP1 has a role in these proliferative
responses, mature T cells were isolated and purified from the
lymph nodes and spleen. Stimulation of mature T cells was
initiated by crosslinking the TCR with agonistic anti-CD3
antibodies, and co-stimulation was provided by crosslinking
CD28 with the corresponding antibodies. T-cell proliferation
was measured by the amounts of tritiated thymidine
incorporated through DNA synthesis. When compared with
RIP1+/+ and RIP1K45A/K45A control T cells, a dramatic defect
in proliferation responses was observed in RIP1t− /− T cells
(Figure 4a). In further analyses of proliferative responses,
increases in T-cell numbers were determined at various time
points after activation and growth curves were generated.
The numbers of activated RIP1− /− T cells barely increased
during a 6-day period in culture, whereas exponential growth
ensued in activated RIP1+/+ and RIP1K45A/K45A T cells
(Figure 4b).
Given the severely impaired proliferative responses in
RIP1− /− T cells, we analyzed T-cell division kinetics. Mature
T cells were purified from peripheral lymphoid organs,
prelabeled with CellTrace violet, and then stimulated with
anti-CD3 and -CD28 antibodies. When T cells divide, the
CellTrace dye is diluted, resulting in lower fluorescence in
daughter cells. At various times after stimulation of the TCR,
T cells were analyzed by flow cytometry. Cell division was
evident in RIP1+/+ control T cells (73.3%, top right panel,
Figure 4c) and RIP1K45A/K45A T cells (74%, middle right panel,
Figure 4c) at 48 h after stimulation, as indicated by the
population with lower CellTrace fluorescence. Minimal cell
division occurred in RIP1+/+, RIP1K45A/K45A, or RIP1− /−
mutant T cells at 24 h after stimulation. At 48 h, cell division
was significant in RIP1− /− T cells (45.7%, lower right panel,
Figure 4c). However, this division was much less than that in
RIP1+/+ and RIP1K45A/K45A T cells. These results indicate that
normal proliferative responses in mature T cells require RIP1.
Death receptor-induced cell death responses in RIP1− /−
T cells. Given the defects in mature T-cell maintenance and
proliferative responses in RIP1t− /− mice (Figures 1-4), we
sought to determine whether lack of RIP1 impacts death
responses in RIP1− /− T cells. RIP1+/+, RIP1K45A/K45A, and
RIP1− /− thymocytes readily underwent Fas-induced apopto-
sis when stimulated with an agonistic anti-Fas antibody and
Figure 4 Analysis of cell proliferation responses of activated RIP1− /− T cells.
(a) Mature T cells were stimulated with the indicated concentrations of anti-CD3 plus
anti-CD28 (0.2 μg/ml) Abs for 48 h, and proliferation was determined by [3H]
thymidine incorporation. Error bars represent± S.D. of triplicate. cpm, count per
minute. (b) T-cell numbers following activation with anti-CD3 (1 μg/ml)/CD28 (0.2 μg/
ml) Abs were enumerated at the indicated times and growth curves were plotted. (c)
Mature T cells were labeled with CellTrace violet, activated as in panel (b), and flow
cytometric analysis was performed. The gates indicate divided T cells and the first
peak to the right represents undivided T cells at each indicated time point. Histograms
are showing live T cells. Numbers indicate the percentages of divided T cells at each
time point. Data are representative of three independent experiments
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was more pronounced with the addition of cycloheximide
(CHX) (left, Figure 5a). However, RIP1+/+ wild-type and
RIP1K45A/K45A mutant thymic T cells were resistant to TNF
treatment. Interestingly, RIP1− /− T cells displayed hyper-
sensitivity to TNF-induced death responses and became
more sensitive with the addition of CHX (right, Figure 5a).
To investigate the mechanistic nature of the observed cell
death induced by TNFα in RIP1− /− T cells, we
analyzed caspase activities by intracellular staining with
cell-permeable fluorogenic caspase substrates.31 As shown
in Figure 5b (left), untreated RIP1− /− mutant thymocytes
contain basal levels of caspase activities (24.4%) that are
similar to that in untreated RIP1+/+ control (23.8%) and
RIP1K45A/K45A (20.9%) T cells. In contrast, greatly higher
caspase activities were detected in RIP1− /− T cells treated
with TNFα and CHX (72%), than in RIP1+/+ (26.9%) and
RIP1K45A/K45A (31.6%) T cells (right, Figure 5b). To analyze
this observation further, we used the pan-caspase inhibitor
zVAD, which effectively blocked apoptosis induced by cross-
linking of Fas with the agonistic antibody (left, Figure 5c).
Moreover, zVAD effectively prevented death in RIP1+/+,
RIP1K45A/K45A, and RIP1− /− thymocytes treated with TNFα
(right, Figure 5c). This finding indicates that RIP1 inhibits
caspase-dependent apoptosis induced by TNFα in thymo-
cytes. However, RIP1 does not protect against Fas-induced
apoptosis in thymocytes.
RIP1 inhibits apoptosis during TCR-induced proliferative
responses. TCR-induced proliferative responses are
accompanied by cell death in wild-type mature T cells. It is
unclear whether the observed proliferation defect in RIP1− /−
T cells (Figure 4) is due to increased cell death responses. To
test this possibility, we isolated mature T cells from the
peripheral lymphoid organs and stimulated them through the
TCR and CD28. At various times after activation, cell death
was analyzed by staining with propidium iodide (PI) and flow
cytometry. Significant cell death (35–50% PI+) in the activated
wild-type T cells was observed at every time point analyzed
(top, Figure 6a). However, compared with the RIP1+/+ and
RIP1K45A/K45A control T cells, greatly increased death was
detected in RIP1− /−mutant T cells, as indicated by higher PI+
populations (60–80% PI+) at all three time points (bottom
versus top and middle panels, Figure 6a).
In the same assay, T cells were prelabeled with CellTrace.
Two-color flow cytometry allows simultaneous analyses
of T-cell proliferative responses. At 24 h after stimulation,
RIP1+/+, RIP1K45A/K45A, and RIP1− /− T cells did not divide (left
column, Figure 6a). At 48 h after stimulation, 44.9% of control
RIP1+/+ T cells and 37.8% of RIP1K45A/K45A T cells had divided
one or more times (middle column, Figure 6a). However, there
was minimal division of RIP1− /− T cells at this time point
(11.2%, middle, Figure 6a). Similarly, at a later time point
(72 h), there was dramatically less cell division in RIP1− /−
T cells (24.8%) than in control RIP1+/+ T cells (48.3%) or
RIP1K45A/K45A T cells (49.6%). These data indicate that RIP1
deletion resulted in defective T-cell division as well as
enhanced cell death.
Further analysis was performed to determine whether
enhanced cell death in activated RIP1− /− T cells was the
result of apoptosis, which is dependent on caspase activation.
To do so, mature T cells were activated through stimulation of
CD3 and CD28 and labeled by cell-permeable substrates,
which turn fluorogenic upon caspase cleavage.31 Intracellular
caspase activity was then measured by flow cytometry.
Interestingly, activated RIP1− /− T cells contain greatly
increased caspase activity compared with RIP1+/+ and
RIP1K45A/K45A T cells that had been activated for 16 h
(Figure 6b). This caspase activity also correlated with an
increase in cell death, as shown by positive staining with
SYTOX AADvanced dead cell stain at the 16 h time point
(Figure 6b). Furthermore, western blotting analysis also
showed increased cleavage of pro-caspase 3 in activated
RIP1− /− T cells (Figure 6c). These results indicate that RIP1
promotes survival by suppressing TCR-induced caspase
activation.
Given that RIP1 is protecting T cells from increased
caspase activity and apoptosis, we next investigated a
potential in vivo trigger that could cause the RIP1t− /−
peripheral T-cell defect. As RIP1− /− thymocytes are sensitive
to TNFα-mediated apoptosis in vitro, an in vivo TNFα blockade
was performed by treating RIP1t− /− mice with anti-TNFa
blocking antibody or isotype control every 3.5 days. After
2 weeks, the percentage of CD3+ T cells in the spleen and
lymph nodes had increased (Figure 7a) and resulted in a
significant rescue of peripheral T-cell numbers in the spleen
and lymph nodes (Figure 7b). This indicates that RIP1 helps
maintain T-cell homeostasis by protecting T cells from TNFα-
mediated apoptosis.
Discussion
Since its initial cloning 420 years ago,9 the physiological
function of RIP1 in T cells has not been fully understood,
mainly owing to perinatal lethality of RIP1− /−mice.10 Although
RIP1 associates with the signaling complex of TNFR1 or Fas,
neither of the two death receptors was essential during mouse
development or lymphocyte development. Prior studies have
indicated that RIP1 may be essential for T-cell development,
becauseRIP1− /− fetal liver cells failed to reconstitute the T-cell
compartment of immune-deficient recipient mice,15,26 and
mice lacking RIP1 in HSCs/Ps contain few T cells.27 However,
our current data showed that RIP1 is dispensable in thymic
development, as deletion of RIP1 at the pro/pre-T-cell stage
using LckCre resulted in no defect in immature thymocyte
profiles (Figures 2 and 3). Although dramatically decreased,
mature T cellswere present in significant numbers in RIP1t− /−
mice (Figures 2 and 3), unlike the near complete blockage of
T-cell development when RIP1 is deleted in HSCs/Ps.26,27
These results clearly demonstrate a temporal requirement for
RIP1 in HSCs/Ps26,27 and mature T cells (Figures 2 and 3) but
less so in pro/pre-T cells or immature T cells (Figure 3). The
conditional mouse model also has a selective defect in
necroptosis, owing to the K45A mutation inactivating the
kinase activity. However, our data show that the kinase activity
of RIP1 is dispensable in the T-cell compartment (Figure 1). As
the KD of RIP1 has been implicated in necroptosis and not in
apoptosis, this further supports the hypothesis that RIP1 is
functioning to protect T cells from apoptosis.
Although RIP1 may bind to Fas, cell death responses were
largely intact (Figure 5a), indicating that RIP1 is dispensable in
T-cell death regulation by RIP1
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Figure 5 Death receptor responses in RIP1− /− T cells. Thymocytes were treated as indicated with or without 30 μg/ml CHX for 16 h. (a) Thymocytes were stained with PI,
and the percentages (mean±S.D. of triplicate) of cell death (PI+) were determined by flow cytometry. (b) CellEvent Caspase 3/7 Green Detection Reagent was incubated with
thymocytes for 30 min after treatment; representative flow plots show caspase activity via cleavage of the fluorogenic caspase substrate. (c) Thymocytes incubated and analyzed
as in panel (a) with the addition of 50 μM zVAD where indicated. Data are representative of three independent experiments
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Fas-induced signaling. There have been data showing that
RIP1 could either promote or inhibit apoptosis induced by
TNFα. Wild-type primary cells are generally resistant to TNFα
treatment. We found that deletion of RIP1 dramatically
sensitized immature T cells to TNF-induced death responses
(Figure 5a). In contrast, intrinsic cell death responseswere not
affected by a lack of RIP1 in T cells (data not shown).
Therefore, RIP1 provides protection against cell death in a
pathway-specific manner. Previous studies, including ours,
indicate that RIP1 perinatal lethality is due to uncontrolled
FADD/caspase 8-mediated apoptosis and RIP3-mediated
necrosis. However, T cell-specific ablation of RIP1 demon-
strates that its main function in T cells is to primarily protect
against apoptosis (Figure 6), not necrosis. This indicates that,
while RIP1 does regulate apoptosis and necrosis, it may do so
in a cell-type-specific manner, for example, protecting against
apoptosis in T cells but protecting against RIP3-mediated
necrosis in HSCs/Ps.27
We have previously shown that the few T cells derived from
adoptively transferred RIP1− /− fetal liver cells displayed a
severe defect in proliferation responses upon stimulation of
the TCR. However, it was not clear whether this defect was
due to abnormal development when RIP1 was absent in
HSCs/Ps. This T-cell proliferation defect was recapitulated in
Figure 6 Cell death responses during TCR-induced activation. (a) Mature T cells
were isolated from the periphery, labeled with Celltrace Violet, and stimulated with
anti-CD3 (1 μg/ml) and anti-CD28 (0.2 μg/ml) antibodies for the indicated times.
Mature T cells were harvested, stained with PI, and analyzed by two-color flow
cytometry. (b) Mature T cells were isolated and stimulated as in panel (a) for 16 h.
T cells were then incubated with CellEvent Caspase 3/7 Green Detection Reagent for
30 min or stained with SYTOX AADvanced Dead Cell Stain and analyzed using a flow
cytometer. (c) Western blotting of peripheral T cells with the indicated genotype for
caspase 3 after stimulation with anti-CD3/CD28 for 48 h. Data are representative of
three independent experiments
Figure 7 In vivo TNFα blockade in RIP1t− /− mice. (a) Representative two-color
flow cytometric plots showing the T cell (CD3+) and B cell (B220+) and (b) total T-cell
numbers in the indicated peripheral lymphoid organs of RIP1t− /− mice treated with
anti-TNFα blocking antibody or isotype control for 2 weeks. *Po0.05, **Po0.01
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the current study, in which RIP1 was deleted in lineage-
committed T cells, definitively showing that RIP1 is involved in
mature T-cell proliferation (Figures 4a–c). Most importantly,
this phenotype may be due not only to increased death in
activated T cells but also to impaired cell division capability
(Figure 6a). In addition to inhibiting apoptosis and necroptosis,
RIP1 has a cell-death-independent function of activating the
canonical NF-κB pathway, which has been best studied in the
context of TNFR1 signaling. As stimulation of the TCR can
activate the NF-κB pathway and the MAPK and AKT path-
ways, it is possible that TCR-induced activation of the NF-κB
pro-survival pathway involves a function of RIP1.
Dysregulation of not only TCR signaling but also uncon-
trolled cell death can have far-reaching implications for
disease progression and proper immune system function.
Hyperactivity of the TNF pathway has been associated with
several chronic autoimmune and inflammatory diseases, such
as psoriasis, rheumatoid arthritis, and multiple sclerosis.
Although anti-TNFα treatment has been shown to be effective
in some cases, a more specific approach, such as targeting
RIP1, could have more success and fewer side effects.
Uncovering how RIP1 functions, especially in T cells, which
are major mediators of autoimmune/inflammatory conditions,
is essential to the discovery of targeted therapies and
treatments. Alternatively, as this study shows that RIP1 is
essential for T-cell maintenance, targeting RIP1 in T cells
could be used as a treatment for T-cell leukemia and
lymphomas to induce apoptosis and reduce T-cell numbers.
In summary, our data provide clear evidence that RIP1 has a
critical role in maintenance of the mature T-cell compartment,
which could contribute to immune disorders, including
immunodeficiency. However, the kinase activity itself is
dispensable in T-cell development and maintenance. Previous
studies show that lack of RIP1 causes necroptosis, leading to
inflammation in neonatal tissues.24 In the adult skin, it appears
that the K45Amutation helps suppress inflammatory diseases
in mice deficient in SHARPIN.28 Therefore, rather than
targeting the whole RIP1 protein, selectively blocking the
kinase activity, which mediates necroptosis, could be con-
sidered as a strategy to help manage certain inflammatory
conditions owing to necroptosis.28 However, current studies
remain incomplete in understanding the complicated regula-
tory circuitry mediated by RIP1. Further investigations would
help reveal more details in the molecular mechanism involving
RIP1 and its role in a variety of autoimmune/inflammatory
diseases and cancer.
Materials and Methods
Mice. Mice containing a conditional knockout allele of RIP1 (RIP1f/f or RIP1K45A/K45A)
were described elsewhere.28 To generate T-cell-specific RIP1 knockout mice, RIP1f/f
mice were crossed with LckCre transgenic mice generated in Dr. C Wilson’s
laboratory29 and originally obtained from Taconic (Hudson, NY, USA). All of the animal
studies were approved by the Institutional Animal Care and Use committee at Thomas
Jefferson University. The LckCre transgene was genotyped by PCR using the primers
5′-CCGAAATTGCCAGGATCAGG-3′ and 5′-CTTACCTGTAGCCATTGCAGCTAG-3′.
PCR-mediated genotyping was performed as described. RIP1+/+ littermates from
RIP1+/f Lckcre+ × RIP1+/f mating crosses were used as controls whenever possible.
Otherwise, age/sex-matched RIP1+/+ mice resulting from RIP1+/f Lckcre+ × RIP1+/f
mating crosses were used as controls.
Western blotting analysis. Total thymocytes were isolated from mice with
various genotypes. Mature T cells were purified by sorting from the spleen and
lymph nodes using a FACS Aria (BD Biosciences, San Jose, CA, USA) and
activated by 1 μg/ml anti-CD3 and 0.2 μg/ml anti-CD28 antibodies. Cells were lysed
in cold RIPA buffer containing 50 mM Tris pH 8.0, 150 mM NaCl, 1% Nonidet P-40,
0.5% Na-deoxycholate, 0.1% SDS, 1 mM phenylmethyl sulphonyl fluoride, and
proteinase inhibitor cocktail (Roche, Indianapolis, IN, USA). Proteins (40 μg) were
separated on a 10% or 15% SDS-PAGE gel and transferred to a nitrocellulose
membrane. Membranes were stained with Ponceus S (Sigma-Aldrich, St. Louis,
MO, USA) as a loading/transfer control. Antibodies specific for RIP1 (BD
Biosciences, Catalog no. 610459) or caspase 3 (BD Biosciences Catalog no.
611048) were incubated with the membrane overnight at 4 °C then with HRP-
conjugated goat anti-mouse antibody (1/10 000) (Vector Laboratories, Burlingame,
CA, USA). Chemiluminescent signals were detected using a Signals A FluorChem
M Western Blot Imaging machine (ProteinSimple, Inc., San Jose, CA, USA).
Flow cytometry. Lymph nodes, spleen, and thymus were isolated from 2- to 4-
month-old mice of the indicated genotype. Single-cell suspensions were made and
red blood cells were depleted via hypotonic lysis. Cells were stained on ice with anti-
CD3 and anti-CD4 (BD Pharmingen, San Diego, CA, USA) and anti-CD8 and anti-
B220 (Caltag, Buckingham, UK) fluorochrome-conjugated antibodies in PBS
containing 3% BSA, 0.5 mM EDTA, and 0.1% sodium azide for 30 min, washed
twice with PBS, acquired on an LSR II flow cytometric analyzer (BD Biosciences),
and analyzed using the Flowjo software (Treestar, Ashland, OR, USA). Cell
numbers were calculated using either a hemacytometer or Countess Automated
Cell Counter (Invitrogen, Carlsbad, CA, USA). T-cell numbers were calculated by
multiplying total cell number by the percentage of CD3+ cells. Unpaired two-tailed t-
tests were performed to obtain P-values comparing the cellularity of RIP1+/+,
RIP1K45A/K45A, and RIP1t− /− mice.
T-cell proliferation assays. Mature T cells were purified from the spleen and
lymph nodes from mice of the indicated genotypes by staining with anti-Thy1.2
antibody (BD Pharmingen) and sorting using a FACS Aria (BD Biosciences).
Purified T cells (105) were seeded into 96-well round-bottom plates coated with
1 μg/ml anti-CD3 antibodies in complete RPMI media (cRPMI) that contains 10%
FBS, 2 mM L-Glutamine, penicillin (100 U/ml), streptomycin (100 μg/ml), and
β-mercaptoethanol (5 μM) with the addition of anti-CD28 antibodies (0.2 μg/ml).
After 40-h incubation at 37 °C with 5% CO2, 1 μCi of [
3H] thymindine was added
before an additional 8-h incubation. Cells were collected using a Mach Harvester 96
(Tomtec, Hamden, CT, USA) and incorporation was measured using a Wallac 1205
Betaplate Counter (Perkin Elmer, Waltham, MA, USA). For growth curve analysis,
purified T cells were seeded in a 24-well plate coated with 1 μg/ml anti-CD3
antibodies in cRPMI with 0.2 μg/ml anti-CD28 antibodies. Cells were enumerated at
the indicated times using a Countess Automated Cell Counter (Invitrogen). For cell
division kinetics, cells were labeled using the CellTrace Violet Cell Proliferation
Kit (Invitrogen), as per the manufacturer’s instructions. At the indicated time points,
1 μg/ml PI was added and the cells were analyzed by two-color flow cytometry.
Cell death assays. Thymocytes (105) were seeded in 96-well flat-bottom
plates in cRPMI with various concentrations of either Jo2 monoclonal anti-mouse
Fas antibody (BD Pharmingen) or TNFα for 16 h. To inhibit caspases, thymocytes
were incubated with 50 μM zVAD-fmk for 1 h prior to stimulations. After incubation,
1 μg/ml PI was added and the percentage of cell killing was measured by flow
cytometry.
Caspase activity measurement. CellEvent Caspase 3/7 Green Flow
Cytometry Assay Kit (Invitrogen) was used to measure caspase acitivty in
thymocytes and mature peripheral T cells as per the manufacturer’s instructions.
Briefly, after incubation of thymocytes with 50 ng/ml TNFα or mature T cells with
1 μg/ml anti-CD3 and 0.2 μg/ml anti-CD28 antibodies for 16 h, CellEvent Caspase
3/7 Green Detection Reagent was added and incubated with cells for 30 min at
37 °C with 5% CO2. Samples were analyzed using an LSR II flow cytometric
analyzer (BD Biosciences) and analyzed using the Flowjo software (Treestar). In
some cases, SYTOX AADvanced Dead Cell Stain (Invitrogen) was used to stain
for dead cells. For in vivo TNFα blockade, mice were treated every 3.5 days for
2 weeks by intraperitoneal injection with 100 μg of anti-TNFα antibody (MP6-XT22,
Biolegend, San Diego, CA, USA), IgG1 isotype control (Biolegend). After 2 weeks of
treatment, lymph nodes and spleen were isolated, single-cell suspensions were
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made, and lymphocyte populations were determined by FACS analysis using an
LSR II (BD Biosciences).
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